A Two-Part, Randomized Phase III, Double-Blind, Multicenter Trial Assessing The Efficacy And Safety of Pertuzumab In Combination With Standard Chemotherapy Vs. Placebo Plus Standard Chemotherapy In Women With Recurrent Platinum-Resistant Epithelial Ovarian Cancer And Low HER3 mRNA Expression
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007574/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This two-part, multicenter study will evaluate the safety, tolerability and efficacy of
pertuzumab in combination with standard chemotherapy in women with recurrent
platinum-resistant epithelial ovarian cancer. In the non-randomized Part 1 safety run-in,
participants will receive pertuzumab plus either topotecan or paclitaxel. In the randomized,
double-blind Part 2 of the study, participants will receive either pertuzumab or placebo in
combination with chemotherapy (topotecan, paclitaxel, or gemcitabine).
提供机构：
Vivli
创建时间：
2021-12-23
